Clinical trial design in scleroderma: Where are we and where do we go next?

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL.71, 2012, Pages

  Chung, Lorinda ^a   Denton, Christopher P ^b   Distler, Oliver ^c   Furst, Daniel E ^d   Khanna, Dinesh ^e   Merkel, Peter A ^f  

^a STANFORD UNIVERSITY   (United States)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Biological markers; Clinical trials; Outcome assessment; Systemic scleroderma

Indexed keywords

BIOLOGICAL MARKER; BOSENTAN; CYCLOPHOSPHAMIDE; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PLACEBO;

CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; DIFFUSE SCLERODERMA; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; FEASIBILITY STUDY; FINGER ULCER; FORCED VITAL CAPACITY; HUMAN; IMMUNOMODULATION; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; NEGLECTED DISEASE; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RARE DISEASE; REVIEW; SCLERODERMA; SKIN FIBROSIS; SKIN MANIFESTATION; SKIN PROTECTION; STUDY DESIGN; TREATMENT INDICATION; VALIDATION PROCESS;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HUMANS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 84867353980     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. MEDSGER T: Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 2003; 29: 255-73.
2. MAYES M, TROJANOWSKA M: Genetic factors in systemic sclerosis. Arthritis Res Ther 2007; 9 (Suppl. 2): S5.
3. STEEN VD: Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005; 35: 35- 42.
4. KHANNA D, LOVELL DJ, GIANNINI E et al.: Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis 2008; 67: 703-9.
5. DISTLER O, BEHRENS F, PITTROW D et al.: Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. Arthritis Rheum 2008; 59: 867-75.
6. MERKEL P, SILLIMAN N, CLEMENTS P et al.: Patterns and predictors of change in outcome measures in clinical trials in scleroderma an individual patient meta-analysis of 629 subjects with diffuse scleroderma. Arthritis Rheum 2012.
7. AMJADI S, MARANIAN P, FURST DE et al.: Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, doubleblind, randomized controlled trials. Arthritis Rheum 2009; 60: 2490-8.
8. CLEMENTS P, LACHENBRUCH P, SIEBOLD J et al.: Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
9. FURST DE, CLEMENTS PJ, STEEN VD et al.: The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998; 25: 84-8.
10. STEEN VD, MEDSGER TA: Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-44.
11. STEEN VD, MEDSGER TA: Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001; 44: 2828-35.
12. WELLS AU, HANSELL DM, RUBENS MB et al.: Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 1997; 40: 1229-36.
13. HOYLES RK, ELLIS RW, WELLSBURY J et al.: A multicenter, prospective, randomized, double- blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54: 3962-70.
14. GOH NS, DESAI SR, VEERARAGHAVAN S et al.: Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248-54.
15. KHANNA D, DISTLER O, AVOUAC J et al.: Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol 2009; 36: 2356-61.
16. DENTON CP, AVOUAC J, BEHRENS F et al.: Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. Arthritis Res Ther 2011; 13: 114.
17. FURIE R, PETRI M, ZAMANI O et al.: A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918-30.
18. TASHKIN DP, ELASHOFF R, CLEMENTS PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-66.
19. KORN JH, MAYES M, MATUCCI-CERINIC M et al.: Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50: 3985-93.
20. MATUCCI-CERINIC M, DENTON CP, FURST DE et al.: Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo- controlled trial. Ann Rheum Dis 2011; 70: 32-8.
21. MERKEL PA, HERLYN K, MARTIN RW et al.: Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002; 46: 2410-20.
22. MOUTHON L, MESTRE-STANISLAS C, BEREZNE A et al.: Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis. Ann Rheum Dis 2010; 69: 214-7.
23. HERRICK AL, ROBERTS C, TRACEY A et al.: Lack of agreement between rheumatologists in defining digital ulceration in systemic sclerosis. Arthritis Rheum 2009; 60: 878-82.
24. KHANNA D, POIRAUDEAU S, GELHORN H et al.: Development and content validity of the hand disability in systemic sclerosis--digital ulcers (HDISS-DU) scale. Arthritis Rheum 2011; 63 (10 Suppl.): S726.
25. CHUNG L, LIU J, PARSONS L et al.: Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138: 1383- 94.
26. OVERBEEK MJ, VONK MC, BOONSTRA A et al.: Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J 2009; 34: 371-9.
27. JOHNSON SR, PATSIOS D, HWANG DM, GRANTON JT: Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension. J Rheumatol 2006; 33: 2347-50.
28. IMPENS AJ, WANGKAEW S, SEIBOLD JR: The 6-minute walk test in scleroderma--how measuring everything measures nothing. Rheumatology 2008; 47 (Suppl. 5): v68-69.
29. KHANNA D, HAYS RD, MARANIAN P et al.: Reliability and validity of the university of california, los angeles scleroderma clinical trial consortium gastrointestinal tract instrument. Arthritis Car Res 2009; 61: 1257-63.
30. KHANNA D, FURST DE, MARANIAN P et al.: Minimally important differences of the UCLA scleroderma clinical trial consortium gastrointestinal tract instrument. J Rheumatol 2011; 38: 1920-4.
31. GRIGGS RC, BATSHAW M, DUNKLE M et al.: Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab 2009; 96: 20-6.